Proteases

Companies Proteases

PeproTech GmbH, Germany

PeproTech was established in 1988 by a group of scientists who focussed their efforts on the development and production of recombinant cytokines for life-science research. Today, PeproTech is a world leader in supplying high quality cytokine products including more than 350 E. coli, insect, and mamm more

News Proteases

• Heptares provides Gpcr expertise to new European drug discovery consortium

  Heptares Therapeutics is joining a group of European academic and industry researchers known as the ‘K4DD’ (‘Kinetics for Drug Discovery’) Consortium to investigate binding kinetics or ‘kinotypic’ properties of drug-receptor complexes. The five-year program will focus on important drug target classe more

• Medivir has initiated a phase I clinical trial with its cathepsin K inhibitor MIV-711

  Medivir AB announced that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases. Maris Hartmanis, CEO of Mediv more

• Specificity by Ring Size

  New drug candidates require testing in animal models prior to approval for clinical use. A recently developed antagonist based on a bicyclic peptide inhibited the human serine protease plasma kallikrein potently and selectively. However, the inhibitor was ‘too’ selective, not inhibiting murine plasm more

White papers Proteases

• Altered Expression of Broad Range of Protease Genes in SH-SY5Y Neuroblastoma Cells after Bortezomib Exposure
  

  Neuroblastoma cell lines can be models for the responsiveness of neuroblastomas to chemotherapy-induced cell death as well as for the sensitivity of untransformed neuro-nal cells to toxic side-effects of chemotherapy. Both phenom-ena are relevant to neuroblastoma cells exposed to bortezomib, a proteasome inhibitor in clinical use. It has been shown previously that neuroblastoma cell lines are prone to undergo apoptosis when treated with bortezomib, but the precise molecular mechanism has not been revealed. In addition to this, peripheral neuropathy is the main side effect of chemotherapy that includes bortezomib more

• Enzymatic Protein Digest for Mass-spectrometric Analysis
  

  The main focus in proteomic studies is on the identification of proteins in given biological samples. Proteins isolated and separated from a given sample (e.g., whole cell lysates, blood or tissue, protein complexes) by immunoprecipitation or affinity chromatography or two-dimensional electrophoresis must be proteolytically cleaved in the course of sample preparation for identification and characterization. A reproducible cleavage pattern of digested proteins is a prerequisite for the unambiguous identification of these proteins by mass spectrometry (MS). more

Publications Proteases

• Identification of ClpP substrates in Caulobacter crescentus reveals a role for regulated proteolysis in bacterial development

  Summary Energy‐dependent proteases ensure the timely removal of unwanted proteins in a highly selective fashion. In Caulobacter crescentus, protein degradation by the ClpXP protease is critical for cell cycle progression; however, only a handful of substrates are currently known. Here, we use a more

• The physiological response of protease inhibition in dystrophic muscle

  Abstract Duchenne muscular dystrophy (DMD) is caused by production of a nonfunctional dystrophin gene product and a failure to accumulate functional dystrophin protein in muscle cells. This leads to membrane instability, loss of Ca2+ homeostasis, and widespread cellular injury. Associated with t more

• Proteases in Mycobacterium tuberculosis pathogenesis: potential as drug targets

  TB is still a major global health problem causing over 1 million deaths per year. An increasing problem of drug resistance in the causative agent, Mycobacterium tuberculosis, as well as problems with the current lengthy and complex treatment regimens, lends urgency to the need to develop new antitub more

Market studies Proteases

• Medivir AB (MVIRB) - Financial and Strategic SWOT Analysis Review

  Medivir AB (Medivir) is a research focused pharmaceuticals company engaged in the development of drugs against widespread diseases such as hepatitis C, with proteases as its target enzyme. The company specializes in developing selective inhibitors that regulate the function of proteases in various d more

Websites Proteases